
## **Stefanie Hennig**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/465366/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. British Journal of Clinical Pharmacology, 2022, 88, 403-415.	1.1	2
2	Population pharmacokinetic model for onceâ€daily intravenous busulfan in pediatric subjects describing <scp>timeâ€associated</scp> clearance. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1002-1017.	1.3	6
3	Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools. Antibiotics, 2022, 11, 758.	1.5	2
4	Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. Clinical Pharmacokinetics, 2021, 60, 17-51.	1.6	23
5	Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation. Cancer Chemotherapy and Pharmacology, 2021, 88, 379-391.	1.1	9
6	Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein–Barr virus–specific T cells. American Journal of Transplantation, 2021, 21, 3465-3471.	2.6	13
7	Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer Chemotherapy and Pharmacology, 2021, 88, 499-512.	1.1	4
8	CPT: Pharmacometrics & Systems Pharmacology – Inception, Maturation, and Future Vision. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 649-657.	1.3	6
9	Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. British Journal of Clinical Pharmacology, 2021, , .	1.1	3
10	Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing—A Translational Example for Intensive Care Units. Pharmaceutics, 2021, 13, 2128.	2.0	3
11	Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review. Clinical Pharmacokinetics, 2020, 59, 1357-1392.	1.6	29
12	What "Impact―Do NLME Publications Have Outside Our Community?. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 191-194.	1.3	1
13	Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?. Clinical Pharmacokinetics, 2019, 58, 389-399.	1.6	20
14	An evaluation of the userâ€friendliness of Bayesian forecasting programs in a clinical setting. British Journal of Clinical Pharmacology, 2019, 85, 2436-2441.	1.1	27
15	Pharmacometrics in Australasia—Twenty Years of Population Approach Group of Australia and New Zealand. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 701-704.	1.3	3
16	Pseudomonas aeruginosa eradication therapy and risk of acquiring Aspergillus in young children with cystic fibrosis. Thorax, 2019, 74, 740-748.	2.7	15
17	Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virusâ€infected children in relation to treatment outcomes. British Journal of Clinical Pharmacology, 2019, 85, 2066-2075.	1.1	11
18	Tacrolimus exposure early after lung transplantation and exploratory associations with acute cellular rejection. European Journal of Clinical Pharmacology, 2019, 75, 879-888.	0.8	5

STEFANIE HENNIG

#	Article	IF	CITATIONS
19	Quizzing for success: Evaluation of the impact of feedback quizzes on the experiences and academic performance of undergraduate students in two clinical pharmacokinetics courses. Currents in Pharmacy Teaching and Learning, 2019, 11, 742-749.	0.4	15
20	Aspergillus and progression of lung disease in children with cystic fibrosis. Thorax, 2019, 74, 125-131.	2.7	32
21	Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients. AAPS Journal, 2018, 20, 14.	2.2	4
22	Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV-infected Children and the Effect on Treatment Outcomes. Pediatric Infectious Disease Journal, 2018, 37, 349-355.	1.1	12
23	Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis: an Update. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	3
24	Antimicrobial stewardship in paediatric oncology: Impact on optimising gentamicin use in febrile neutropenia. Pediatric Blood and Cancer, 2018, 65, e26810.	0.8	8
25	Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis. Clinical Pharmacokinetics, 2018, 57, 1017-1027.	1.6	17
26	Comparison of methods to estimate glomerular filtration rate in paediatric oncology patients. Journal of Paediatrics and Child Health, 2018, 54, 141-147.	0.4	10
27	Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials― Clinical Pharmacokinetics, 2018, 57, 1471-1472.	1.6	2
28	Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw461.	1.3	26
29	Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?. Cancer Chemotherapy and Pharmacology, 2017, 80, 15-25.	1.1	10
30	A Population Pharmacokinetic Model of Gentamicin in Pediatric Oncology Patients To Facilitate Personalized Dosing. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	17
31	Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer?. Clinical Therapeutics, 2017, 39, 1840-1848.	1.1	6
32	Prediction of glycaemic control in young children and adolescents with type 1 diabetes mellitus using mixed-effects logistic regression modelling. PLoS ONE, 2017, 12, e0182181.	1.1	6
33	Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. Journal of Clinical Pharmacology, 2016, 56, 705-713.	1.0	5
34	Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 3407-3414.	1.4	26
35	Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 6698-6702.	1.4	33
36	Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the UK. Journal of Pharmacy Practice and Research, 2016, 46, 15-21.	0.5	15

STEFANIE HENNIG

#	Article	IF	CITATIONS
37	Gentamicin Pharmacokinetics and Monitoring in Pediatric Patients with Febrile Neutropenia. Therapeutic Drug Monitoring, 2016, 38, 693-698.	1.0	10
38	Quantitation of the Effect of Azole Antifungals on Tacrolimus Clearance. Journal of Heart and Lung Transplantation, 2016, 35, S236.	0.3	2
39	A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. Paediatric Respiratory Reviews, 2016, 20, 55-66.	1.2	77
40	Population pharmacokinetic drug–drug interaction pooled analysis of existing data for rifabutin and HIV PIs. Journal of Antimicrobial Chemotherapy, 2016, 71, 1330-1340.	1.3	10
41	Quantitative determination of the enantiomers of methadone in human plasma and saliva by chiral column chromatography coupled with mass spectrometric detection. Talanta, 2016, 149, 142-148.	2.9	19
42	Effect of <i>SLCO1B1</i> Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 617-620.	1.4	12
43	A systematic review of treatment outcomes with weight-based dosing of chemotherapy in obese adult patients with acute leukemia or lymphoma. Leukemia and Lymphoma, 2016, 57, 981-984.	0.6	3
44	Gentamicin Pharmacokinetics and Monitoring in Pediatric Febrile Neutropenic Patients. Therapeutic Drug Monitoring, 2016, , 1.	1.0	8
45	A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced Data. PLoS ONE, 2016, 11, e0152700.	1.1	4
46	Tacrolimus pharmacokinetics after kidney transplantation – Influence of changes in haematocrit and steroid dose. British Journal of Clinical Pharmacology, 2015, 80, 1475-1476.	1.1	3
47	Population pharmacokinetics of phenytoin in critically ill children. Journal of Clinical Pharmacology, 2015, 55, 355-364.	1.0	9
48	Comparing Dosage Adjustment Methods for Once-Daily Tobramycin in Paediatric and Adolescent Patients with Cystic Fibrosis. Clinical Pharmacokinetics, 2015, 54, 409-421.	1.6	31
49	Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant Patients. Therapeutic Drug Monitoring, 2014, 36, 62-70.	1.0	70
50	Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 428-434.	0.3	17
51	Improved prediction of tacrolimus concentrations early after kidney transplantation using theoryâ€based pharmacokinetic modelling. British Journal of Clinical Pharmacology, 2014, 78, 509-523.	1.1	67
52	Concordance between criteria for covariate model building. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 109-125.	0.8	5
53	To Cap or Not to Cap: Chemotherapy Dosing in Obese Adult Hematology Patients. Clinical Pharmacology and Therapeutics, 2014, 95, 356-358.	2.3	5
54	Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis. Clinical Pharmacokinetics, 2013, 52, 289-301.	1.6	59

STEFANIE HENNIG

#	Article	IF	CITATIONS
55	Optimizing disease progression study designs for drug effect discrimination. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 587-596.	0.8	6
56	Phenytoin Loading Doses in Adult Critical Care Patients: Does Current Practice Achieve Adequate Drug Levels?. Anaesthesia and Intensive Care, 2013, 41, 602-609.	0.2	5
57	Ethically Attractive Doseâ€Finding Designs for Drugs With a Narrow Therapeutic Index. Journal of Clinical Pharmacology, 2012, 52, 29-38.	1.0	3
58	Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin. Journal of Clinical Pharmacology, 2012, 52, 347-360.	1.0	16
59	PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool. Computer Methods and Programs in Biomedicine, 2012, 108, 789-805.	2.6	61
60	Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies. Journal of Clinical Pharmacology, 2009, 49, 323-335.	1.0	9
61	The Influence of Underlying Assumptions on Evaluating the Relative Merits of Concentration-Controlled and Dose-Controlled Trials. Clinical Pharmacology and Therapeutics, 2009, 86, 70-76.	2.3	3
62	Comparison of Dose-Finding Designs for Narrow-Therapeutic-Index Drugs: Concentration-Controlled vs. Dose-Controlled Trials. Clinical Pharmacology and Therapeutics, 2009, 86, 62-69.	2.3	8
63	Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis – a population pharmacokinetic study. British Journal of Clinical Pharmacology, 2008, 65, 502-510.	1.1	58
64	A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. British Journal of Clinical Pharmacology, 2007, 63, 438-450.	1.1	45
65	Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients. Clinical Pharmacokinetics, 2006, 45, 1099-1114.	1.6	54
66	A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxy-itraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosis. Biomedical Chromatography, 2006, 20, 343-348.	0.8	20
67	Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI??). Therapeutic Drug Monitoring, 2005, 27, 205-207.	1.0	10
68	Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 521-545.	0.8	38